Compare PFN & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFN | PRME |
|---|---|---|
| Founded | N/A | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 681.9M | 553.2M |
| IPO Year | 2004 | 2022 |
| Metric | PFN | PRME |
|---|---|---|
| Price | $6.26 | $3.13 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $7.56 |
| AVG Volume (30 Days) | 506.0K | ★ 2.5M |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,632,000.00 |
| Revenue This Year | N/A | $7.06 |
| Revenue Next Year | N/A | $47.01 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 55.28 |
| 52 Week Low | $6.32 | $2.67 |
| 52 Week High | $7.65 | $6.94 |
| Indicator | PFN | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 16.91 | 56.17 |
| Support Level | N/A | $3.14 |
| Resistance Level | $7.18 | $3.72 |
| Average True Range (ATR) | 0.08 | 0.22 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 0.00 | 63.44 |
PIMCO Income Strategy Fund II is a closed-ended fixed income mutual fund. The company's primary investment objective is to seek high current income, consistent with the preservation of capital. The fund invests in different range of securities, such as corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, municipal bonds and notes, short-term instruments, sovereign Issues, preferred Securities and others.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.